A. Curioni-Fontecedro

Discipline

Psychologie (1)

Type de document

Articles (5) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Treatment (5) thérapie (4) Chemotherapy (4) Therapeutics (4) Patients (4) Chemotherapy (4) Patients (4) maladie (3) survie (3) Inhibitors (3) Trials (3) Theater (3) Survival (3) Radiotherapy (3) Months (3) Human beings (3) Lungs (3) Drama (3) Acting (3) Radiotherapy (3) maladie (3) norme (2) sécurité (2) analyse (2) dosage (2) adulte (2) procès (2) taux (2) Surgery (2) Identification (2)

Documents écrit par A. Curioni-Fontecedro (5) | parle de A. Curioni-Fontecedro (0)

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
D. König et al. (11 juil. 2023)
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
S. Popat et al.
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
A. Curioni-Fontecedro et al.
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
S. Peters et al.
Searching for targets for the systemic therapy of mesothelioma.
R.A. Stahel et al. (2015)